ImaginAb, Inc. appoints Jennifer Keppler as President and Chief Operating Officer
December 13, 2010
Los Angeles, CA: December 13, 2010 – ImaginAb, Inc., a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, announced the appointment of Jennifer Keppler as President and COO.
Ms. Keppler has more than 20 years experience in the molecular imaging field, most notably in Positron Emission Tomography (PET). The announcement was made by CEO, Dr. Christian Behrenbruch. In this role, Ms. Keppler will provide strategic direction and oversee all aspects of operations at ImaginAb. This will include leveraging relationships among diverse research channels to develop a pipeline of clinical imaging agents in development to address unmet needs in cancer and immunology.
“We are extremely pleased to have someone of Jenny’s caliber join and lead our team in developing new agents in clinical imaging. Jenny’s track record of success in start-up operations and regulatory approvals, along with her industry experience and leadership will be invaluable to ImaginAb,” Dr. Christian Behrenbruch said. Dr. Anna Wu, ImaginAb’s co-Founder and Chief Scientific Advisor commented, “As we take our products into the clinic, both our internal pipeline and our pharma collaborations will benefit from Jenny’s extensive experience”
Ms. Keppler is an acknowledged leader in regulatory aspects of molecular imaging tracers. Immediately prior to joining ImaginAb, Ms. Keppler was the Director of Research and Operations for the Banner Alzheimer’s Institute, a leading international source for Alzheimer’s disease prevention and care. She previously served as COO for a start-up, wholly-owned subsidiary of CTI Molecular Imaging, which was acquired by Siemens. Prior to Siemens, Ms. Keppler was the Executive Director of the Institute for Clinical PET, the leading professional association that drove the original Medicare and FDA approvals for PET. Before this, she was the business lead for start-up PET centers at the University of Southern California and at the Banner Good Samaritan PET center, a division in Banner Health.
Ms. Keppler earned an MBA from the University of Southern California; a Bachelors of Science of Business in Marketing from the University of Phoenix and Associates of Science in Nuclear Medicine Technology from Butler University. Ms. Keppler is also author of numerous scientific papers on clinical PET/radiopharmaceuticals and diagnostic imaging.
Founded in 2007 by UCLA Faculty (Dr. Rob Reiter and Dr. Anna Wu), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.